Scholar Rock reported a net loss of $91.0 million for the fourth quarter of 2025 as it prepares for the anticipated 2026 U.S. launch of apitegromab. The company secured a significant $550 million debt facility to support commercialization and is awaiting FDA reinspection of its fill-finish site to resubmit its BLA.

Scholar Rock recorded no revenue for Q3 2025 while net loss widened due to substantial increases in administrative and R&D expenses tied to commercialization efforts.

Scholar Rock reported a net loss of $110 million for Q2 2025, an increase from $58.5 million in Q2 2024, primarily due to increased research and development and general and administrative expenses as the company prepares for the potential U.S. commercial launch of apitegromab. The company had no revenue for the quarter but maintained a strong cash position of $295 million, expected to fund operations into 2027.

Scholar Rock reported its full year 2024 financial results, highlighting the submission of the apitegromab BLA, progress towards MAA submission, upcoming data readouts, and a strong cash position.

Scholar Rock reported positive topline data from the Phase 3 SAPPHIRE trial of apitegromab in SMA patients and completed enrollment in the Phase 2 EMBRAZE trial for apitegromab in obesity. The company also completed an upsized $345 million public offering. Net loss for the quarter was $64.5 million, or $0.66 per share.

Scholar Rock reported a net loss of $58.5 million for the second quarter of 2024. The company is progressing with its clinical trials, including the Phase 3 SAPPHIRE trial for apitegromab in SMA, and the Phase 2 EMBRAZE trial for apitegromab in obesity.

Scholar Rock reported no revenue for Q1 2024. Net loss was $56.9 million, or $0.59 per share. The company's cash, cash equivalents, and marketable securities totaled $238 million as of March 31, 2024, expected to fund operations into the second half of 2025. Topline data from the Phase 3 SAPPHIRE trial is expected in 4Q 2024.

Scholar Rock reported a net loss of $165.8 million for the full year ended December 31, 2023. The company is on track to release topline data for its Phase 3 SAPPHIRE trial of apitegromab in spinal muscular atrophy in the fourth quarter of 2024 and to initiate a Phase 2 proof-of-concept trial with apitegromab in combination with a GLP-1 RA in mid-2024. The company ended the year with approximately $280 million in cash, cash equivalents, and marketable securities.

Scholar Rock reported a net loss of $42.4 million for Q3 2023, with no revenue recorded. The company completed enrollment for the Phase 3 SAPPHIRE trial and presented data supporting SRK-181. A $98 million public offering was completed, extending the cash runway into the second half of 2025.

Scholar Rock reported a net loss of $37.9 million for the second quarter of 2023. The company's cash, cash equivalents, and marketable securities were approximately $249 million as of June 30, 2023, expected to fund operations into 2025.

Scholar Rock reported a net loss of $39.4 million, with $0 revenue for the quarter ended March 31, 2023. The company had approximately $275 million in cash, cash equivalents, and marketable securities as of March 31, 2023, which is expected to fund operations into 2025.

Scholar Rock reported full year 2022 financial results, with revenue at $33.2 million and a net loss of $134.5 million. The company ended the year with approximately $315 million in cash, cash equivalents and marketable securities.

Scholar Rock reported a net loss of $43.3 million, with revenue at $0 for Q3 2022. The company's cash, cash equivalents, and marketable securities were approximately $343.7 million as of September 30, 2022.

Scholar Rock reported a net loss of $44.0 million for the second quarter of 2022. Enrollment continues to advance in the pivotal Phase 3 SAPPHIRE trial for apitegromab in SMA. The company's cash, cash equivalents, and marketable securities were approximately $371 million as of June 30, 2022.

Scholar Rock reported revenue of $33.2 million for Q1 2022, primarily from the Gilead collaboration, and a net loss of $8.0 million, or $0.21 per share. The company is prioritizing its clinical programs, reducing workforce by 25%, and expects its cash runway to extend into the fourth quarter of 2023.

Scholar Rock reported full year results, with a net loss of $131.8 million and revenue of $18.8 million. The company ended the year with approximately $253 million in cash, cash equivalents, and marketable securities.

Scholar Rock reported third quarter 2021 financial results, with a net loss of $37.5 million, or $1.02 per share, compared to a net loss of $23.6 million, or $0.79 per share for the quarter ended September 30, 2020. Revenue was $5.5 million, compared to $3.0 million for the quarter ended September 30, 2020. The company is on track to initiate the Phase 3 pivotal trial evaluating apitegromab in patients with non-ambulatory Type 2 and Type 3 SMA by year-end 2021.

Scholar Rock reported a net loss of $30.7 million, or $0.84 per share, and revenue of $4.6 million for the quarter ended June 30, 2021. The company's cash and cash equivalents totaled approximately $282 million at the end of the quarter.

Scholar Rock reported a net loss of $27.7 million, or $0.76 per share, and revenue of $4.7 million for the quarter ended March 31, 2021. The company's cash, cash equivalents and marketable securities were approximately $315 million.

Scholar Rock reported a net loss of $86.5 million for the full year ended December 31, 2020. The company ended the year with approximately $341 million in cash, cash equivalents, and marketable securities.

Scholar Rock reported a net loss of $23.6 million, or $0.79 per share, for the third quarter ended September 30, 2020. Revenue for the quarter was $3.0 million. The company's cash, cash equivalents, and marketable securities totaled $116.3 million as of September 30, 2020.

Scholar Rock reported a net loss of $19.3 million, or $0.65 per share, for the quarter ended June 30, 2020. Revenue for the quarter was $3.9 million, related to the Gilead collaboration. The company's cash, cash equivalents, and marketable securities totaled $141.2 million as of June 30, 2020.

Scholar Rock reported a net loss of $17.1 million, or $0.58 per share, for the quarter ended March 31, 2020. Revenue was $5.0 million, related to the Gilead collaboration. As of March 31, 2020, Scholar Rock had $160.6 million in cash, cash equivalents, and marketable securities.

Scholar Rock reported a net loss of $51.0 million for the year ended December 31, 2019. The company's cash, cash equivalents, and marketable securities totaled $157.4 million as of December 31, 2019.